ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
about
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemiaTargeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival.Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.ATM protein is deficient in over 40% of lung adenocarcinomas.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsCyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Targeting the ATR-CHK1 Axis in Cancer TherapyCurrent Treatment of Chronic Lymphocytic Leukemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.The DNA damage response pathway in normal hematopoiesis and malignancies.Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function.Genetic variants in thyroid cancer distant metastasesTherapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.Around and beyond 53BP1 Nuclear Bodies.ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.Susceptibility of ATM-deficient pancreatic cancer cells to radiation.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.TrapSeq: An RNA Sequencing-Based Pipeline for the Identification of Gene-Trap Insertions in Mammalian Cells.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.Advances in therapeutic targeting of the DNA damage response in cancer.The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and RadiosensitisationThe therapeutic significance of mutational signatures from DNA repair deficiency in cancerCD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM
P2860
Q30823304-0772D124-01B0-4739-8880-3C54FA08E668Q33648911-7136D585-56F2-4C3B-9725-B0BCA699120DQ33705389-4B4A940C-D5F0-45FC-83F7-BA0CBDCE093BQ33925006-D82CA95D-4192-4832-9ACB-7C848F205AEDQ37325003-BFD3C984-0A70-4DC1-8AE4-E6339F592003Q37508792-412F9033-4717-4B0C-A67B-7B6C21AC8A24Q37628924-BE419F77-A256-41D1-BDA6-F2006337CAEAQ37641736-E4A89C23-C5A8-46EF-A5CD-42D5FCF4937CQ37716464-A1D27610-86BD-4EB5-883F-2A0BD0174F8EQ38608688-85F9A2DB-D4AA-43FC-9C71-E5A960B1A2C7Q38698806-DEA7D474-9EA4-4E76-A98B-5252DEB962C5Q38817102-0470037C-775F-418C-B448-F27AEF1AD2CBQ39129372-09679B98-33A1-4654-ACBF-E4775C611B1CQ39263974-E731DE73-8840-4ACF-A29D-EDFF8D38C937Q39434457-D6B9EDCD-103B-4D01-855C-3AF4BF82A5AFQ41344084-9D4523F0-D2B0-49B3-8F12-9FBE4B00AC31Q41640645-9252D6FF-1E40-4D0A-8178-830E5E1DAF50Q46062200-829605D6-8530-4D19-BE17-1CF86E40B7B0Q47186808-E47C7E4D-4A7D-4FA3-A07E-20555B668511Q47622968-A0B5CAD4-5364-483A-A76B-3ABBAD56236FQ47687840-B2867E78-4EC3-4D9C-B4C4-C2FD145620E7Q47786231-166C5C50-FA17-49E7-A575-6C03D68C4A04Q48112143-73521DA0-BCF4-4781-B982-ABAC44C6C261Q48218378-790B0D88-F0A6-4712-A13A-E36F481F98DCQ49679908-863871A1-2909-4CB4-981A-B32867E89147Q50509483-82B5DA28-DED8-4E5D-BD4C-7DA732FBB961Q51800946-14281131-1ACF-4278-B720-CA26EACCF8D9Q54977196-32F0CBC8-F698-47DC-BA08-7ACD14B5E96FQ55306606-8D87F977-40C6-455C-B0EB-F0E0177F1420Q58734520-46DF4954-E673-4F0A-BDA7-E7CFE5C83B40Q58771249-9434903F-B681-4901-89CD-0392AC9855C6Q58798783-18ECB365-5431-41CA-B344-CFDCF6C09102
P2860
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@en
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@nl
type
label
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@en
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@nl
prefLabel
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@en
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@nl
P2093
P50
P6366
P1154
2-s2.0-84974577895
P1433
P1476
ATR inhibition induces synthet ...... ic lymphocytic leukemia cells.
@en
P2093
Angelo Agathanggelou
Ceri Oldreive
Edward Smith
Jeff Brown
Malcolm Taylor
Nicholas Davies
Peter Hillmen
P304
P356
10.1182/BLOOD-2015-05-644872
P407
P5530
P577
2015-11-12T00:00:00Z
P5875
P6179
1064122721
P6366
2177777322